Explainer
How US prescription drug prices are set: list prices, rebates and PBMs
What a US patient pays for a drug depends on a chain of deals. Pharmacy benefit managers (PBMs) build health plans' formularies, and patients' cost sharing can be coinsurance, a percentage of the list price.[1] Drugmakers pay PBMs rebates for preferred formulary placement.[2] An FTC staff report found the three largest PBMs processed nearly 80% of prescriptions dispensed by US pharmacies in 2023.[3] Government programs set prices differently: Medicaid collects rebates from about 780 drugmakers, and Medicare now negotiates prices for certain high-spending drugs without generic or biosimilar competition.[4][5]
The US has no single price for a prescription drug. A patient’s share may be tied to the list price, while drugmakers pay rebates after the fact to the pharmacy benefit managers that run health plans’ drug benefits in return for preferred placement on a formulary.[2][1] Government programs use their own formulas.[4] This page explains the main pieces and the rules that govern them.
This page is general information, not medical or financial advice. Do not stop or change a medicine because of cost without talking to your prescriber or pharmacist, who may know of cheaper alternatives or assistance programs.
List prices, formularies and what patients pay
Pharmacy benefit managers (PBMs) develop a plan’s formulary, the list of brand, generic and specialty drugs it covers. Patients’ cost sharing can be coinsurance, a percentage of the list price, or a copayment, a fixed amount not tied to the list price.[1]
Rebates and PBM pay
Drug companies pay PBMs rebates to have their drugs placed favorably on a formulary. The rebates come after the prescriptions are filled. The Labor Department says that because these payments are often set as a share of the list price, PBMs have an incentive to pick drugs with high list prices and high rebates.[2]
In its November 2026 rule, the Labor Department describes rebates as manufacturer discounts in return for preferred formulary placement, paid to the PBM after prescriptions are filled. It says manufacturer payments defined by reference to list price incentivize high-list-price, high-rebate formulary choices.[2] It distinguishes pass-through pricing, where the plan pays a discounted price plus an administrative fee, from spread pricing, where the plan pays a higher price and little or no fee and the PBM keeps the spread over what it pays the pharmacy.[6]
How concentrated the PBM market is
A July 2024 FTC staff report found that the three largest PBMs processed nearly 80% of the roughly 6.6 billion prescriptions dispensed by US pharmacies in 2023, and the top six more than 90%.[3] It said the largest PBMs are vertically integrated with the biggest health insurers and with specialty and retail pharmacies. The Commission voted 4-1 to release the report, with Commissioner Melissa Holyoak voting no.[7]
A second staff report, in January 2025, focused on specialty generic drugs. It found that the three largest PBMs’ affiliated pharmacies earned more than $7.3 billion in dispensing revenue above estimated acquisition cost on those drugs from 2017 to 2022.[8] These are findings of FTC staff, not court rulings.
New disclosure rules for employer plans
On 2 November 2026 the Labor Department published a final rule requiring PBMs to disclose their direct and indirect compensation to the fiduciaries of large self-insured employer health plans covered by ERISA. It takes effect on 4 January 2027 and applies to plan years beginning on or after 1 July 2027.[9]
Medicaid and Medicare
Medicaid relies on rebates. Under the Medicaid Drug Rebate Program, about 780 drugmakers sign rebate agreements with HHS in exchange for state Medicaid coverage of most of their drugs, and all 50 states and DC cover drugs through it.[4]
Medicare now negotiates some prices directly. CMS negotiates for certain high-spending, single-source drugs that have no generic or biosimilar competition.[5] Negotiated prices for the first 10 Part D drugs took effect on 1 January 2026, and prices for 15 more, including Ozempic and Wegovy, take effect on 1 January 2027.[10][11] A third round of 15 drugs, including the first Part B drugs, will have prices effective in 2028.[12] The program is explained in medicare-drug-price-negotiation, and Part D costs for 2027 in Medicare in 2027.
Read next
Medicare Drug Price Negotiation Program
How Medicare negotiates drug prices: the 10 drugs priced from 2026, 15 from 2027 including Ozempic, the 2028 list with first Part B drugs, and what is next.
Questions readers ask
What is a pharmacy benefit manager?
A PBM manages prescription benefits for health plans. Among other things it builds the plan's formulary, the list of covered drugs. An FTC staff report found the three largest PBMs processed nearly 80% of the roughly 6.6 billion US prescriptions in 2023.[1][3]
What are drug rebates?
The Labor Department describes rebates as discounts drugmakers pay, after prescriptions are filled, in return for preferred placement on a formulary. It says payments tied to list price give PBMs an incentive to favor high-list-price, high-rebate drugs.[2]
Why does the list price matter if I have insurance?
Cost sharing can be coinsurance, a percentage of the list price, or a copayment, a fixed amount not tied to the list price.[1]
What is spread pricing?
Under spread pricing a plan pays the PBM a set price for a drug and little or no administrative fee, and the PBM keeps the difference between that and what it pays the pharmacy.[6]
Sources
· 12 claims from 5 publishers
Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.
- [1]
PBMs build a plan's formulary, the list of covered drugs, and cost sharing may be coinsurance, a percentage of the list price, or a fixed copayment not tied to list price. confirmedas of 2026-11-02
- Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure (final rule) · Federal Register (Employee Benefits Security Administration, U.S. Department of Labor) · Primary source · 2026-11-02 · Background, Formulary Development and Design: "PBMs develop a self-insured group health plan's prescription drug formulary" (retrieved 2026-11-07)
- [2]
The Labor Department describes rebates as discounts drugmakers pay, after prescriptions are filled, in return for preferred formulary placement, and says payments defined by list price give PBMs an incentive to favor high-list-price, high-rebate drugs. confirmedas of 2026-11-02· interpretation
- Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure (final rule) · Federal Register (Employee Benefits Security Administration, U.S. Department of Labor) · Primary source · 2026-11-02 · Section 3.2, Payments From Drug Manufacturers; also "Rebates are paid to the PBM periodically after the prescriptions are filled" (retrieved 2026-11-07)
- [3]
An FTC staff report found the three largest pharmacy benefit managers processed nearly 80% of the roughly 6.6 billion prescriptions dispensed by US pharmacies in 2023, and the top six more than 90%. confirmedas of 2024-07-09
- FTC Releases Interim Staff Report on Prescription Drug Middlemen · U.S. Federal Trade Commission · Primary source · 2024-07-09 (retrieved 2026-11-07)
- [4]
Under the Medicaid Drug Rebate Program, about 780 drugmakers sign rebate agreements with HHS in exchange for state Medicaid coverage of most of their drugs, and all 50 states and DC cover prescription drugs under the program. confirmedas of 2026-11-07
- Medicaid Drug Rebate Program · Medicaid.gov (Centers for Medicare & Medicaid Services) · Primary source · Also: manufacturers must have a National Drug Rebate Agreement "in exchange for state Medicaid coverage of most of the manufacturer’s drugs" (retrieved 2026-11-07)
- [5]
Under the Negotiation Program CMS directly negotiates prices of certain high-expenditure, single-source drugs without generic or biosimilar competition; on 13 March 2026 it announced that the manufacturers of all 15 third-cycle drugs, and of the drug selected for renegotiation, chose to participate. confirmedas of 2026-03-13
- CMS Announces Manufacturer Participation in Third Cycle of Medicare Drug Price Negotiation · U.S. Centers for Medicare & Medicaid Services · Primary source · 2026-03-13 · Opening: "CMS directly negotiates the prices of certain high expenditure, single source drugs without generic or biosimilar competition" (retrieved 2026-10-11)
- [6]
Under spread pricing a plan pays the PBM a set price for a drug and little or no administrative fee, and the PBM keeps the difference between that price and what it pays the pharmacy; under pass-through pricing the plan pays a discounted price plus an administrative fee. confirmedas of 2026-11-02
- Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure (final rule) · Federal Register (Employee Benefits Security Administration, U.S. Department of Labor) · Primary source · 2026-11-02 · Section 3.1; next: "The PBM will instead retain the spread between the price reimbursed to" the pharmacy and the plan price (retrieved 2026-11-07)
- [7]
The FTC staff report said the largest PBMs are vertically integrated with the largest health insurers and with specialty and retail pharmacies; the Commission voted 4-1 to release it, with Commissioner Melissa Holyoak voting no. confirmedas of 2024-07-09
- FTC Releases Interim Staff Report on Prescription Drug Middlemen · U.S. Federal Trade Commission · Primary source · 2024-07-09 (retrieved 2026-11-07)
- FTC Releases Interim Staff Report on Prescription Drug Middlemen · U.S. Federal Trade Commission · Primary source · 2024-07-09 (retrieved 2026-11-07)
- [8]
A second FTC staff report in January 2025 found that the three largest PBMs' affiliated pharmacies earned more than $7.3 billion in dispensing revenue above estimated acquisition cost on specialty generic drugs from 2017 to 2022. confirmedas of 2025-01-14
- FTC Releases Second Interim Staff Report on Prescription Drug Middlemen · U.S. Federal Trade Commission · Primary source · 2025-01-14 · Key findings; the release says the report "analyzed all specialty generic drugs dispensed from 2017 to 2022" (retrieved 2026-11-07)
- [9]
A Labor Department final rule published on 2 November 2026 requires PBMs to disclose their direct and indirect compensation to fiduciaries of large self-insured ERISA health plans; it takes effect on 4 January 2027 for plan years beginning on or after 1 July 2027. confirmedas of 2026-11-02
- Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure (final rule) · Federal Register (Employee Benefits Security Administration, U.S. Department of Labor) · Primary source · 2026-11-02 · Summary; Dates: "This regulation is effective January 4, 2027. This regulation is applicable to plan years beginning on or after July 1, 2027." (retrieved 2026-11-07)
- [10]
Medicare's negotiated prices for the first 10 Part D drugs, including Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara and Fiasp/NovoLog, took effect on 1 January 2026. confirmedas of 2026-03-11
- Key Facts About Medicare Drug Price Negotiation · KFF · Secondary source · 2026-03-11 · Selected Drugs for Implementation Year 2026 (retrieved 2026-10-11)
- Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026 · U.S. Centers for Medicare & Medicaid Services · Primary source · 2024-08-15 · Fact sheet lists negotiated prices for 10 drugs covered under Medicare Part D (retrieved 2026-10-11)
- [11]
In the second cycle Medicare reached agreement on all 15 selected Part D drugs, including Ozempic and Wegovy; the prices take effect on 1 January 2027, and CMS estimated they would have saved about $8.5 billion (about 36% lower net spending) had they applied in 2024. confirmedas of 2026-01-27
- CMS Announces Selection of Drugs for Third Cycle of Medicare Drug Price Negotiation Program, Including First-Ever Part B Drugs · U.S. Centers for Medicare & Medicaid Services · Primary source · 2026-01-27 · Also: "saved an estimated $8.5 billion in net covered prescription drug costs ... approximately 36% lower net spending" (retrieved 2026-10-11)
- [12]
On 27 January 2026 CMS selected 15 drugs for the third cycle, including the first Part B drugs, with prices effective 1 January 2028; the list is Anoro Ellipta, Biktarvy, Botox, Cimzia, Cosentyx, Entyvio, Erleada, Kisqali, Lenvima, Orencia, Rexulti, Trulicity, Verzenio, Xeljanz and Xolair, and Tradjenta was picked for renegotiation. confirmedas of 2026-01-27
- CMS Announces Selection of Drugs for Third Cycle of Medicare Drug Price Negotiation Program, Including First-Ever Part B Drugs · U.S. Centers for Medicare & Medicaid Services · Primary source · 2026-01-27 · Selected drug list and renegotiation (Tradjenta) (retrieved 2026-10-11)
Revision history (1)
- Page created.
Created Nov 7, 2026. Last reviewed by an editor on Nov 8, 2026. Next scheduled review: Feb 7, 2027.
Cite this page
"How US prescription drug prices are set: list prices, rebates and PBMs." ContentLora, updated Nov 7, 2026. https://contentlora.com/explain/how-prescription-drug-prices-are-set
Spotted an error? Suggest a correction or emailcorrections@contentlora.com.